|
1. Paoletti P, Butti G, Knerich R, Gaetani P, Assietti R.Chemotherapy for malignant gliomas of the brain: a review of ten-years experience. Acta Neurochir (Wien). 103, 35-46 (1990).
2. Boehm T, Folkman J, Browder T, O''Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390, 404-7 (1997)
3. Linskey ME, Gilbert MR. Glial differentiation: a review with implications for new directions in neuro-oncology. Neurosurgery. 36, 1-21; discussion 21-2 (1995).
4. Raymond W. Ruddon. Cancer biology.
5. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J. 5, 2924-33 (1991).
6. Langston AW, Gudas LJ Retinoic acid and homeobox gene regulation.
Curr Opin Genet Dev. 4, 550-5 (1994).
7. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J. 5, 2924-33 (1991).
8. 陳博明主任 急性骨髓性白血病化學治療最近的進展 台北榮民總醫院腫瘤科
9. Dai C, Holland EC. Glioma models. Biochim Biophys Acta. 1551, M19-27 (2001)
10. Yat-Sen Ho. Pathology of the brain tumor
11. G. Jean Harry. In vivo techniques for the assessment of neurotoxicity. Environment health. 106, 131-158 (1998).
12. Janet D . Oligodendrocytes as glucocorticoids target cells: Functional analysis of the glycerol phosphate dehydrogenase gene. J. Neurosci Res. 59, 436-445 (2000).
13. Shirsat NV, Kayal JJ, Shaikh S, Mehta A. Growth inhibition and differentiation of C6 glioma cells on treatment with hmba. Cell Biol Int. 25, 621-7 (2001).
14. Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res. 52, 1988-92 (1992).
15. Ram Z, Samid D, Walbridge S, Oshiro EM, Viola JJ, Tao-Cheng JH, Shack S, Thibault A, Myers CE, Oldfield EH. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate.
Cancer Res. 54, 2923-7 (1994).
16. Stockhammer G, Manley GT, Johnson R, Rosenblum MK, Samid D, Lieberman FS. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg. 83, 672-81 (1995).
17. Baker MJ, Brem S, Daniels S, Sherman B, Phuphanich S. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol. 59, 239-42 (2002).
18. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 14, 105-13 (1978).
19. Hargreaves AJ, Yusta B, Avila J, Hesketh JE, Aranda A, Pascual A.Sodium butyrate induces major morphological changes in C6 glioma cells that are correlated with increased synthesis of a spectrin-like protein. Brain Res Dev Brain Res. 45, 291-5 (1989).
20. Hirschfeld A, Bressler J. Effect of sodium butyrate on S-100 protein levels and the cAMP response. J Cell Physiol. 133, 158-62 (1987).
21. Rius C, Vilaboa N, Mata F, Aller P. Differential modulation of the expression of the intermediate filament proteins vimentin and nuclear lamins A and C by differentiation inducers in human myeloid leukemia (U-937, HL-60) cells.
Exp Cell Res. 208, 115-20 (1993).
22. Jang TH, Sun SH. Alterations in Ca2+ signaling, and c-fos and nur77 expression are associated with sodium butyrate-induced differentiation of C6 glioma cell.
Chin J Physiol . 43, 149-58 (2000).
23. Marin-Husstege M, Muggironi M, Liu A, Casaccia-Bonnefil P. Inhibition of histone deacetylase activity is necessary for oligodendrocyte lineage progression, J. Neurosci. 22, 10333-45 (2002)
24. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo) 29, 1-6 (1976).
25. Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res. 47, 3688-91(1987).
26. Corelli F, Massa S, Stefancich G, Mai A, Artico M, Panico S, Simonetti N. Antibacterial and antifungal compounds. VIII. Synthesis and antifungal activity of pyrrol derivatives similar to trichostatin A. Tanpakushitsu Kakusan Koso. 34, 1069-81 (1989).
27. Massa S, Artico M, Corelli F, Mai A, Di Santo R, Cortes S, Marongiu ME, Pani A, La Colla P. Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. J Med Chem. 33, 2845-91(1990).
28. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 265,17174-9 (1990).
29. Jung M, Brosch G, Kolle D, Scherf H, Gerhauser C, Loidl P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.J Med Chem. 42,4669-79 (1999).
30. Cancer Chemother Pharmacol 2001
31. 陳煌輝碩士論文. 1998. 國立陽明大學生物藥學研究所.
32. Shi MG, Huang Q, Dong J, Sun ZF, Lan Q. Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug. Ai Zheng. 21, 1090-4 (2002).
33. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 77, 3957-61 (1980).
34. Miskimins R, Srinivasan R, Marin-Husstege M, Miskimins WK, Casaccia-Bonnefil P. P27Kip1 enhances myelin basic protein gene promoter activity. J. Neurosci. Res. 67,100-105. (2000)
35. Zezula J, Casaccia-Bonnefil P, Ezhevsky SA, Osterhout DJ, Levine JM, Dowdy SF, Chao MV, Koff A.P21Cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal .EMBO. 2, 27-34. (2000).
36. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K.Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 96, 7797-802 (1999).
37. Gliemroth J, Zulewski H, Arnold H, Terzis AJ. Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin. Neurosurg Rev 2003 Mar 29 (Epub ahead of print)
38. Kumano T, Mutoh T, Nakagawa H, Kuriyama M.HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, trk, and morphological differentiation with fatal outcome in PC12 cells.
Brain Res. 859, 169-72 (2000).
39. Wachtershauser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.Carcinogenesis. 22, 1061-7 (2001).
40. Prasanna P, Thibault A, Liu L, Samid D.Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem. 66, 710-6 (1996).
41. Choi JW, Jung SE. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. J Pharmacol Exp Ther. 1,572-9 (1999).
42. Ana Lucia B. Cabral ,Kil S. Lee, and Vilma R. Martins Regulation of the Cellular Prion Protein Gene Expression Depends on Chromatin Conformation J. Biol. Chem., 277,5675-5682 (2002).
43. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85, 2643-53(1995).
44. Kimura S, Yoshino A, Katayama Y, Watanabe T, Fukushima T. Growth control of C6 glioma in vivo by nerve growth factor. J. Neurooncol. 3,199-205 (2002).
|